SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)
Website: www.sinobiopharm.com
(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
APPLICATION FOR CLINICAL TRIAL ON TQF3250 "ORALLY ADMINISTERED, BIASED GLP-1 RECEPTOR AGONIST" APPROVED BY THE NMPA AND FDA

The board of directors (the "**Board**") of Sino Biopharmaceutical Limited (the "**Company**", together with its subsidiaries, the "**Group**") announces that the clinical trial application for its self-developed innovative drug, TQF3250 capsules "orally administered, biased GLP-1 receptor agonist", has been approved by the China National Medical Products Administration (NMPA) and the United States Food and Drug Administration (FDA), intended for weight loss.

TQF3250 is an orally administered, small-molecule, biased GLP-1 receptor agonist. Compared to conventional GLP-1 drugs, TQF3250 selectively activates the cAMP-biased GLP-1 receptor signaling pathway, promotes insulin secretion, while reducing β-arrestin recruitment and receptor endocytosis, thereby prolonging the duration of therapeutic effect. Leveraging its unique mechanism of action, TQF3250 is expected to achieve an improved glycemic and weight control and significantly reduce gastrointestinal side effects. Compared with the injectable formulations of mainstream GLP-1 drugs, its oral administration route offers substantially improved convenience and long-term treatment adherence for patients.

Overweight and obesity have become one of the most severe challenges on public health in the 21st century. As reported by World Obesity Atlas 2025, the global prevalence of overweight and obese adults is expected to climb from 36% in 2000 to 50% by 2030, affecting nearly 3 billion people. This trend is particularly pronounced in China, where 41% of adults have a high BMI (≥25kg/m²) and 9% of adults meet the criteria of obesity (BMI ≥30kg/m²) in 2025. By 2030, the number of adults with a high BMI in China is projected to reach 515 million[1].

In addition to the weight loss indication, the clinical trial application of TQF3250 for the treatment of Type 2 diabetes has been approved by the NMPA. Metabolic diseases are one of the core therapeutic areas the Group focuses on, and the Group aims to provide a broader range of treatment options for patients with its diversified products and a robust pipeline.

Reference:

[1] World Obesity Federation. (2025). World Obesity Atlas 2025. London: World Obesity Federation.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 4 December 2025

As at the date of this announcement, the Board of the Company comprises six executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, and Mr. Tian Zhoushan, and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.